NewsRoom Articles - Page 1271 of 1352

MondayFeb 06, 2017 1:47 pm

Moxian, Inc. (NASDAQ: MOXC) Using Social Media as a Channel to Initiate Online Purchases for Merchants

According to statistics published at ChinaDaily.com (http://nnw.fm/x8NcC), online sales in China have boomed, growing 26.2% year-on-year to reach over five trillion yuan ($751.7 billion) in 2016. With this in mind, researchers and specialists worldwide are looking at China to learn how to initiate more online purchases, but it is not just China’s developed e-commerce market that has caught people’s attention. The mobile generation led everyone to focus on mobile marketing, but companies are realizing that they have to cater their services to users across all devices in order to reach their full audience potential. According to a McKinsey survey (http://nnw.fm/3jfV4),…

MondayFeb 06, 2017 9:11 am

National Waste Management Holdings, Inc. (NWMH) – A Leading, National Solid Waste Service Company

National Waste Management Holdings, Inc. (OTC: NWMH) is making a strong play in the waste industry and taking major steps to turn the page on its growth story. Over the course of three decades, the company has become a notable provider of solid waste management services to Florida’s west coast and New York’s upstate region. By specializing in the collection, hauling, removal and recycling of debris, garbage and waste from construction and demolition sites and, now, through vertical integration, the company is growing, expanding its reach, and adding new services to its portfolio, all at affordable rates. Comprehensively, National Waste…

ThursdayFeb 02, 2017 2:45 pm

Marinus (NASDAQ: MRNS) Names Michael R. Dougherty to Board, Prepares to Initiate Phase 2 Studies of Ganaxolone

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), on February 1, 2017, named Michael R. Dougherty to its board. A biopharmaceutical company, Marinus is preparing to initiate phase 2 studies of ganaxolone, a drug which treats seizures and anxiety in patients suffering from epilepsy and neuropsychiatric disorders. Dougherty has more than 30 years of experience in the biopharmaceutical industry. Most recently, he served as executive chairman of Celator Pharmaceuticals, Inc. Earlier, he served as CEO and a board member of Kalidex Pharmaceuticals, Inc. Dougherty also served in various capacities during his 10-year tenure with Adolor Corporation, including as president and CEO, a board member, COO, CFO…

ThursdayFeb 02, 2017 1:58 pm

Monster Digital, Inc. (NASDAQ: MSDI) Tapping into Fast-Growing VR Market with High-Performance Cameras, Headsets

Until recently, virtual reality was typically the stuff of science fiction, a concept so innovative and unusual that it seemed highly unlikely to become reality anytime soon. For years, the concept remained almost exclusively tied to the futuristic images depicted by movies such as TRON or The Lawnmower Man. However, with rapid technological advancements in recent years, and due to the efforts of companies such as Facebook (NASDAQ: FB), with its Oculus VR, and Sony Corporation (NYSE: SNE), with its PlayStation VR, virtual reality has now become a part of our day-to-day lives, already having multiple applications in a number…

ThursdayFeb 02, 2017 9:19 am

ChineseInvestors.com, Inc. (CIIX) Revenues Rise For Quarter, Six Months Ended November 30, 2016

ChineseInvestors.com, Inc. (OTCQB: CIIX) filed form 10Q with the SEC on January 23, 2017, stating that it had sharply higher revenues in both the quarter and six months ended November 30, 2016, as compared to the same periods of the prior year. In this filing for its second quarter in fiscal year 2017, it also revised its financials for the year ended May 31, 2016, terming that refiling an immaterial correction. The company reported revenues of $510,944 for the three months ended November 30, 2016. That marked a 133% jump compared to revenues of $219,263 for the same period of…

WednesdayFeb 01, 2017 3:54 pm

Zogenix, Inc. (NASDAQ: ZGNX) Receives Patent for ZX008 in the Treatment of Dravet Syndrome

Zogenix, Inc. (NASDAQ: ZGNX) has been issued a patent by the U.S. Patent Office for its drug candidate ZX008. The award of this patent, according to the company, marks the first time a patent has been issued covering a fenfluramine treatment of Dravet Syndrome and the seizures associated with it (http://nnw.fm/K0ReQ). The patent is seen by the company as offering protection of associated claims through 2033. “This represents the first issued patent covering the treatment of seizures associated with Dravet Syndrome using fenfluramine as an adjunctive therapy, and it is an important milestone for our ZX008 development program,” Stephen J.…

WednesdayFeb 01, 2017 2:30 pm

Social Reality, Inc. (NASDAQ: SRAX) Innovative Ad Technology Offering Stronger Digital & Social Marketing Performance

Any business today knows that, in order to thrive and build a customer base, it needs to develop strong digital marketing awareness and communicate with its target audience virtually in real-time via social media and across any other digital channels. Nowadays, advertising alone is no longer enough. With customers becoming increasingly savvy and competition being tougher than ever, businesses have to look for new, unique ways to stay relevant and improve their digital performance. With the help of Social Reality, Inc. (NASDAQ: SRAX), a leading Internet advertising company offering a wide range of tools to automate the digital advertising market,…

WednesdayFeb 01, 2017 12:43 pm

CytoDyn Inc. (CYDY) Set to Profit from Helping the HIV+

CytoDyn Inc. (OTCQB: CYDY) is set to profit from helping the HIV positive with its lead product candidate, PRO 140. The company is close to submitting a rolling Biologics License Application (BLA) for PRO 140 as a combination therapy with highly active antiretroviral therapy (HAART). The biologic has already been designated a “fast track” product candidate by the FDA, and, earlier this month, the company filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure. Getting PRO 140 to market means CytoDyn Inc. will be…

WednesdayFeb 01, 2017 12:19 pm

GreeneStone Healthcare Corp. (GRST) is “One to Watch”

GreeneStone Healthcare Corp. (OTCQB: GRST), through its subsidiaries, provides medical services in the city of Toronto and the regional municipality of Muskoka, Ontario, Canada. Located 90 minutes north of Toronto in Muskoka, GreeneStone Healthcare’s Addiction and Rehabilitation Treatments segment offers out-patient counseling, coaching, intervention, psychological assessment, and other related services. GreeneStone Muskoka employs the best principles and practices currently available in the treatment of individuals with addiction. To ensure the most comprehensive and effective treatment for its clients, GreeneStone Muskoka treats underlying or co-occurring disorders in tandem with the treatment of addiction. The 36-bed addiction treatment center offers a holistic,…

WednesdayFeb 01, 2017 10:08 am

Marijuana Industry Pushing Toward Federal Acceptance, Expanded Research in 2017

For the marijuana industry, 2016 was a successful year by any standards, reaching an estimated $7 billion in transactions and bringing the total number of states to legalize marijuana for medical and/or recreational purposes to 28. However, deemed America's fastest growing industry in recent years, the market still has some major obstacles to overcome in 2017, such as gaining access to legal banking services, obtaining federal drug reclassification, and more. Removing marijuana from the federal list of Schedule I drugs would be a major step forward for the industry, with massive implications and benefits trickling through to reach cannabis-related product…

Financial news and publishing for public and private companies

Contact us: 512.354.7000